JP7472122B2 - コルチコステロイドを投与する方法 - Google Patents

コルチコステロイドを投与する方法 Download PDF

Info

Publication number
JP7472122B2
JP7472122B2 JP2021525303A JP2021525303A JP7472122B2 JP 7472122 B2 JP7472122 B2 JP 7472122B2 JP 2021525303 A JP2021525303 A JP 2021525303A JP 2021525303 A JP2021525303 A JP 2021525303A JP 7472122 B2 JP7472122 B2 JP 7472122B2
Authority
JP
Japan
Prior art keywords
dose
corticosteroid
urinary
patient
hsd1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021525303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507103A (ja
JP2022507103A5 (cg-RX-API-DMAC7.html
Inventor
カッツ，デイビッド，エー．
Original Assignee
スパロー ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スパロー ファーマシューティカルズ，インコーポレーテッド filed Critical スパロー ファーマシューティカルズ，インコーポレーテッド
Publication of JP2022507103A publication Critical patent/JP2022507103A/ja
Publication of JP2022507103A5 publication Critical patent/JP2022507103A5/ja
Priority to JP2024063590A priority Critical patent/JP2024098991A/ja
Application granted granted Critical
Publication of JP7472122B2 publication Critical patent/JP7472122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021525303A 2018-11-20 2019-08-14 コルチコステロイドを投与する方法 Active JP7472122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063590A JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
US62/769,932 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063590A Division JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Publications (3)

Publication Number Publication Date
JP2022507103A JP2022507103A (ja) 2022-01-18
JP2022507103A5 JP2022507103A5 (cg-RX-API-DMAC7.html) 2022-08-23
JP7472122B2 true JP7472122B2 (ja) 2024-04-22

Family

ID=70774135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525303A Active JP7472122B2 (ja) 2018-11-20 2019-08-14 コルチコステロイドを投与する方法
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Country Status (10)

Country Link
US (2) US12220412B2 (cg-RX-API-DMAC7.html)
EP (1) EP3883578A4 (cg-RX-API-DMAC7.html)
JP (2) JP7472122B2 (cg-RX-API-DMAC7.html)
CN (1) CN113329754A (cg-RX-API-DMAC7.html)
AU (2) AU2019384074B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009653A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120339A1 (cg-RX-API-DMAC7.html)
IL (2) IL319327A (cg-RX-API-DMAC7.html)
MX (2) MX2021005801A (cg-RX-API-DMAC7.html)
WO (1) WO2020106337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス，インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
BR112021015481A2 (pt) * 2019-02-08 2021-12-07 Sanofi Sa Otimização biotecnológica de micro-organismos para a 1,2-desidrogenação de esteroides
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
IL316907A (en) * 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS
AU2024348222A1 (en) * 2023-09-27 2026-04-16 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528308A (ja) 2001-03-23 2004-09-16 ザ ユニバーシティ オブ エディンバラ 脂質プロフィールのモジュレーション
US20050277647A1 (en) 2004-04-29 2005-12-15 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2010121814A1 (en) 2009-04-22 2010-10-28 Ontochem Gmbh Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist
WO2012033070A1 (ja) 2010-09-07 2012-03-15 アステラス製薬株式会社 疼痛治療剤
US20130338169A1 (en) 2004-04-29 2013-12-19 Abbvie Inc. Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) * 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
ATE455547T1 (de) 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
ATE476425T1 (de) 2003-05-29 2010-08-15 Merck Sharp & Dohme Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
WO2005044192A2 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
BRPI0417687A (pt) 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
WO2005097759A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
JP4993407B2 (ja) 2004-08-04 2012-08-08 大正製薬株式会社 トリアゾール誘導体
CN101014578B (zh) 2004-09-16 2011-01-19 安斯泰来制药有限公司 三唑衍生物或其盐
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
JPWO2006080533A1 (ja) 2005-01-31 2008-06-19 持田製薬株式会社 ３−アミノ−１，２，４−トリアゾール誘導体
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
KR20080016649A (ko) 2005-06-16 2008-02-21 화이자 인코포레이티드 Ｎ-(피리딘-2-일)-술폰아미드 유도체
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
WO2007021941A2 (en) 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
MX2008011723A (es) 2006-03-16 2008-09-26 Astellas Pharma Inc Derivado de triazol o su sal.
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
ES2620657T3 (es) 2008-07-03 2017-06-29 Astellas Pharma Inc. Derivado de triazol o sal del mismo
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
CN104303060A (zh) * 2012-03-13 2015-01-21 艾伯维公司 选择或鉴别用于v1B拮抗剂治疗的受试者的方法
US9579322B2 (en) * 2014-07-09 2017-02-28 Eip Pharma, Llc Methods for treating neurologic disorders
CN107613986A (zh) 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
IL316907A (en) 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528308A (ja) 2001-03-23 2004-09-16 ザ ユニバーシティ オブ エディンバラ 脂質プロフィールのモジュレーション
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
US20050277647A1 (en) 2004-04-29 2005-12-15 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20130338169A1 (en) 2004-04-29 2013-12-19 Abbvie Inc. Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2010121814A1 (en) 2009-04-22 2010-10-28 Ontochem Gmbh Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist
WO2012033070A1 (ja) 2010-09-07 2012-03-15 アステラス製薬株式会社 疼痛治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
British Journal of Pharmacology，2018年，175，pp.3784-3796

Also Published As

Publication number Publication date
US20250205227A1 (en) 2025-06-26
US20210393622A1 (en) 2021-12-23
CA3120339A1 (en) 2020-05-28
WO2020106337A1 (en) 2020-05-28
MX2021005801A (es) 2021-08-05
EP3883578A4 (en) 2022-07-27
CN113329754A (zh) 2021-08-31
BR112021009653A2 (pt) 2021-08-17
MX2025002836A (es) 2025-04-02
JP2022507103A (ja) 2022-01-18
IL283069B1 (en) 2025-05-01
IL319327A (en) 2025-05-01
IL283069A (en) 2021-06-30
EP3883578A1 (en) 2021-09-29
US12220412B2 (en) 2025-02-11
AU2025203033A1 (en) 2025-05-22
JP2024098991A (ja) 2024-07-24
AU2019384074B2 (en) 2025-04-10
IL283069B2 (en) 2025-09-01
AU2019384074A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
JP2024098991A (ja) コルチコステロイドを投与する方法
US20220249515A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US10940156B2 (en) Neuroactive steroids, compositions, and uses thereof
TWI784261B (zh) 神經活性類固醇，其組合物及其用途
EP3548014B1 (en) Ketamine for the treatment of menstrually related symptoms
JP2022507103A5 (cg-RX-API-DMAC7.html)
TW202341995A (zh) 用於治療cns相關病症之神經活性類固醇
KR20240006026A (ko) 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20230158033A (ko) 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20200062241A (ko) 시포니모드의 투여 요법
NO332723B1 (no) Anvendelse av glukokortikoidreseptorantagonist for fremstilling av medikamenter til inhibering av kognitiv svekkelse hos voksne med Downs syndrom
JP2019507786A (ja) 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン
EP4243782B1 (en) Tablet for use in treating huntington's disease and method of making the same
JP2019522033A (ja) アルツハイマー病治療に関連するアミロイド関連画像異常の治療または予防方法
US12419881B1 (en) Methods of using radiprodil in the treatment of disorders
JP2019507785A (ja) 炎症状態の急性増悪の治療のための投与レジメン
CN110831590A (zh) 含有培马贝特的医药
JP2024501259A (ja) 静脈内バクロフェンの投与方法
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
HK40101454A (en) Tablet for use in treating huntington's disease and method of making the same
RU2021113995A (ru) Способы введения кортикостероидов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240410

R150 Certificate of patent or registration of utility model

Ref document number: 7472122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150